Dudediligence.

Viking Therapeutics, Inc

VKTXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24$0.00Mar ’25$0.00Jun ’25$0.00Sep ’25$0.00Dec ’25$0.00Mar ’26$0.00Jun ’26
Net income, by quarter
−$24.9MSep ’24−$35.4MDec ’24−$45.6MMar ’25−$65.6MJun ’25−$90.8MSep ’25−$157.7MDec ’25−$158.3MMar ’26−$128.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income−$55.7M−$70.4M−$100.8M−$150.9M−$393.3M
Net income−$55.0M−$68.9M−$85.9M−$110.0M−$359.6M
Operating cash flow−$47.6M−$48.4M−$73.4M−$87.8M−$278.7M
Cash$26.4M$36.6M$55.5M$26.7M$165.8M
Shares outstanding78.2M78.3M100.1M111.6M114.8M